Announcements Trials
Browse Landscape

Status

Completed 6Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 145Observational 6

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 4

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia 2Leukemia, Myeloid, Chronic-Phase 1

Interventions

Surveys and Questionnaires 286Blood Specimen Collection 145Gene Expression Profiling 96Interviews as Topic 83Immunohistochemistry 78Polymerase Chain Reaction 64Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 58Microarray Analysis 55Flow Cytometry 53Radiotherapy 49Amplified Fragment Length Polymorphism Analysis 48Drug Therapy 46Observation 45Biopsy 42Reverse Transcriptase Polymerase Chain Reaction 39Bevacizumab 39Data Collection 35Sorafenib 29Psychiatric Rehabilitation 29Nivolumab 28palbociclib 26In Situ Hybridization, Fluorescence 26Rituximab 25Therapeutics 24Neoadjuvant Therapy 24Hepatectomy 24Docetaxel 24Colonoscopy 24Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Observational × Dasatinib × Clear all
NCT05286528 2023-10-27

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Pfizer

Completed
1,484 enrolled 6 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03885830 2023-01-11

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

UNC Lineberger Comprehensive Cancer Center

Completed
45 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02389972 2017-09-11

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Bristol-Myers Squibb

Completed
128 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02546791 2017-07-26

PASS

Bristol-Myers Squibb

Completed
101 enrolled
Other hematologic neoplasm

Leukemia

NCT01188278 2016-09-30

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Bristol-Myers Squibb

Completed
173 enrolled
Other hematologic neoplasm

Leukemia

NCT02733445 2016-04-11

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Bristol-Myers Squibb

Completed
2,650 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡